“Continuous Weekly Adalimumab Is the Optimal Long-Term Strategy for Patients With Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial”. SKIN The Journal of Cutaneous Medicine, vol. 1, no. 3.1, Oct. 2017, p. s129, doi:10.25251/skin.1.supp.128.